- Home
- DERM vs SLS Comparison
DERM vs SLS Comparison
Compare DERM & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DERM | SLS |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.4M | 706.7M |
| IPO Year | 2021 | 2007 |
Fundamental Metrics
Financial Performance| Metric | DERM | SLS |
|---|---|---|
| Price | $7.13 | $4.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $12.67 | $7.00 |
| AVG Volume (30 Days) | 101.7K | ★ 6.1M |
| Earning Date | 03-25-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.69 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $56,134,000.00 | N/A |
| Revenue This Year | $17.48 | N/A |
| Revenue Next Year | $55.83 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.40 | $0.95 |
| 52 Week High | $9.56 | $6.14 |
Technical Indicators
Market Signals| Indicator | DERM | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 36.56 | 51.69 |
| Support Level | $6.77 | $1.48 |
| Resistance Level | $8.02 | $5.01 |
| Average True Range (ATR) | 0.49 | 0.50 |
| MACD | -0.09 | -0.08 |
| Stochastic Oscillator | 8.43 | 23.70 |
Price Performance
Historical ComparisonAbout DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.